Actively Recruiting
Phase 1 Open-Label Study of LY3439539 Infusions to Assess Cerebrospinal Fluid Biomarker Changes in Symptomatic Alzheimers Disease
Led by Eli Lilly and Company · Updated on 2026-11-04
30
Participants Needed
16
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the drug LY3439539 affects certain proteins in the spinal fluid of people with Alzheimers disease. This Phase 1, open-label study focuses on changes in cerebrospinal fluid biomarkers related to Alzheimers, aiming to better understand the disease process. It is sponsored by Eli Lilly and Company and targets participants with symptomatic Alzheimers disease. Participants will receive multiple doses of LY3439539 administered intravenously. The study is designed as a single group without a placebo comparison. The treatment period includes repeated dosing, followed by a follow-up period lasting up to 24 weeks to assess changes in biomarkers. The total participation time is approximately 9 months with visits roughly once a month. During the study, participants will undergo lumbar punctures for cerebrospinal fluid collection as well as blood tests to measure biomarker levels. Researchers will monitor changes in neurofilament light chain and phospho-tau proteins as primary and secondary outcomes. Safety and pharmacokinetics of LY3439539 will also be assessed. Participants will have regular visits for assessments and monitoring throughout the study duration.
CONDITIONS
Brief Title
A Study of LY3439539 in Participants With Alzheimer's Disease
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here